Founded in 2008, Beijing Kawin Technology Share-Holding Co., Ltd. (“Kawin”; stock code 688687) is a biopharmaceutical company focused on viral and immune diseases, and committed to offering treatment solutions based on our biotech platforms.
On February 14, 2022, Kawin and YiChang HEC ChangJiang Pharmaceutical Co.,Ltd. (hereinafter referred to as HEC Pharm 东 阳...
18 March 2020, Kawin Technology's 赛波唯 (Sofosbuvir Tablets) was approved by National Medical Products Administration...
11 February 2020, Kawin Technology's therapeutic drug of chronic hepatitis C virus (HCV) , Coblopasvir Hydrochloride Caps...
On March 20th, 2018, Beijing TV Morning Beijing aired a special interview, themed as high-end drug for China and better q...
On January 8th, 2018, at the 2017 National Science And Technology Prize ceremony, Dr. Yunde Hou, CAS Academician and Foun...
Focus on the treatment of viral hepatitis C disease
CDMO
US subsidiary